Little Known Facts About RAS-IN-2.
Participant has had any other prior or concurrent malignancy inside 2 yrs prior to enrollment with the subsequent exceptions: adequately handled localized basal mobile or squamous cell carcinoma, or curatively treated in situ carcinoma with the cervix or breast. Other exceptions may be viewed as on sponsor consultation.Third-line MSS/pMMR CRC (Sect